Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinico-pathologic study of primary mediastinal B-cell lymphoma
2006-005794-22Phase 2Completed
- Sponsor
- International Extranodal Lymphoma Study Group
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, doxorubicin, cyclophosphamide, methotrexate, vincristine and 3 more in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by International Extranodal Lymphoma Study Group. Primary endpoint: PET response rate following initial chemo-immunotherapy. Started Nov 2007; status: completed.
02
Drugs
rituximabdoxorubicincyclophosphamidemethotrexatevincristine
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on 2006-005794-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005794-22.